Testosterone after Prostate Cancer
Shalender -- Bhasin, MD
Brigham and Women's Hospital
Presentations in This Video
Menopausal hormone therapy and estrogen sensitive cancers
JoAnn V Pinkerton, MD
University of Virginia
Systemic menopausal hormone therapy is not recommended. However, for women with genitourinary syndrome of menopause who fail lubricants and moisturizers, local low-dose vaginal hormone therapy may be considered, with involvement of the patient’s oncologist. For endometrial cancer survivors, systemic or low dose vaginal hormone therapy may be considered for low-risk cancers but should be avoided in high-risk subtypes. For survivors of epithelial ovarian cancer, vaginal and cervical cancer, hormone therapy can be considered unless the histologic subtypes are estrogen-sensitive histologic subtypes. Risks and benefits of menopausal hormone therapy should be assessed individually including symptoms, response to nonhormone therapies, and quality of life issues. If systemic hormone therapy is considered, one should consider the type of hormone therapy, need for progestational agents, dose, route of administration whether oral or transdermal, duration of use, age at initiation and prior exposure.